Fluvoxamine, a long-standing antidepressant that is inexpensive per dose, may alleviate the debilitating fatigue characteristic of long COVID for countless patients. If validated, this discovery could provide healthcare professionals with their first robust evidence-based pharmaceutical option for a condition that has been largely unresponsive to treatment.
A clinical study examined the medication in Brazilian adults who had suffered from persistent fatigue for no less than 90 days following a confirmed SARS-CoV-2 infection. Throughout a treatment duration of 60 days, fluvoxamine seemed to surpass the effectiveness of a placebo.
Metformin, the diabetes drug evaluated in the same study, showed no significant improvement for patients whose long COVID fatigue was already established.
## A repurposed drug, a stubborn syndrome
Fluvoxamine, sold under the brand name Luvox, is a selective serotonin reuptake inhibitor initially sanctioned for obsessive-compulsive disorder and depression. It garnered interest during the pandemic when smaller studies indicated it might mitigate severe acute COVID by reducing inflammatory signaling. Its application towards long COVID fatigue represents a different hypothesis: that whatever causes the ongoing exhaustion — immune dysregulation, autonomic dysfunction, or lingering viral remnants — may respond to the same anti-inflammatory mechanisms that the drug appears to influence.
Long COVID impacts millions globally. Fatigue is among its most prevalent and debilitating symptoms, preventing patients from participating in work, school, and everyday activities for months or even years following their initial infection.
The outcome seems significant for a patient population that has had limited options. As per the trial findings, fluvoxamine provided consistent advantages for long COVID fatigue. Being an already approved drug with a well-documented safety profile, it may hold promise for clinical application in managing this condition.
## How the trial worked
The study recruited adults in Brazil with verified SARS-CoV-2 infections who had been coping with fatigue for at least three months. Participants were assigned to receive either fluvoxamine, metformin, or a placebo, and were monitored for 60 days. Fatigue and quality-of-life metrics were the primary outcomes measured.
The study employed a Bayesian adaptive design — a statistical framework that continually updates the likelihood of benefit as data accumulate, allowing for an early halt to the trial once clear evidence emerges. Traditional studies depend on fixed sample sizes and p-values calculated post-hoc; Bayesian designs can be swifter and, in principle, more ethical when treatment outcomes are evidently favorable or unfavorable.
The trial authors asserted that the design was as pivotal as the drug’s result, noting that the adaptive methodology reached solid conclusions more effectively than a conventional study would have.
The reported probability figure differs from a classical p-value. It indicates that, based on the trial data, there is a substantial probability that fluvoxamine is more effective than placebo in alleviating fatigue — a strong indication by any reasonable measure.
## Why fluvoxamine and not metformin?
The contrasting outcomes are insightful. Metformin has demonstrated promising signs in previous research targeting *preventing* long COVID when administered during acute infection. However, once fatigue becomes entrenched — sometimes lasting for months — the underlying biology may change. The data imply that metformin does not revert that established condition, at least not within a 60-day timeframe.
The exact mechanism of fluvoxamine in long COVID remains not entirely elucidated. The drug interacts with the sigma-1 receptor, which modulates inflammatory cytokine production, and it also influences platelet activation as well as serotonin signaling in both the gut and brain. Any of these actions could be pertinent to a condition increasingly associated with ongoing immune activation and potential viral reservoirs.
Science Blog has previously reported evidence suggesting that reactivated latent viruses and immune remnants from earlier infections may be driving numerous long COVID cases — a hypothesis that might help clarify why an anti-inflammatory antidepressant could be beneficial.
## Context: what came before
Until now, treatment options for long COVID have been limited. Trials have investigated antivirals, anticoagulants, low-dose naltrexone, and various supplements, with mixed or unclear results. The most significant advancements have stemmed from prevention rather than treatment.
A cohort study indicated that [Paxlovid administered during acute COVID was linked to fewer COVID-19 hospitalizations and a lowered risk of long COVID](https://www.cidrap.umn.edu/covid-19/paxlovid-tied-fewer-covid-19-hospitalizations-reduced-risk-long-covid). This research reinforced the role of antivirals as prevention tools but did not address patients whose symptoms were already present.
This study addresses that void. It appears to be the first substantial randomized trial demonstrating a clinically significant advantage for individuals already experiencing long COVID fatigue.
## What clinicians will do with this
The practical implication is evident: patients seek immediate options, and this finding brings that closer to fruition.
Fluvoxamine is off-patent, affordable, and readily available in most locations. This is crucial for a condition that disproportionately impacts working-age adults and that health systems have struggled to manage at scale.
However, several caveats warrant consideration. The trial lasted for 60 days; the durability of the benefits beyond that period is